Wuhan Wansheng Biotechnology
Finnrick has tested 243 samples from Wuhan Wansheng Biotechnology across 12 products.
Fraud: Based on community reports, we have identified wuhanwanshengbio.com as a fraudulent web site aggressively operating in the name of this vendor. It is most likely entirely unaffiliated with the original company, the fraud is putting the public at risk, so we are temporarily putting all tests under review.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| BPC-157 | 19 | 18 Sep 2025 | 23 Jun 2026 | |||||
| Cagrilintide | 14 | 21 Oct 2025 | 6 May 2026 | |||||
| CJC-1295 | 7 | 29 Oct 2025 | 6 Mar 2026 | |||||
| GHK-Cu | 22 | 4 Aug 2025 | 12 Jun 2026 | |||||
| Ipamorelin | 13 | 11 Aug 2025 | 28 Apr 2026 | |||||
| Melanotan II | 5 | 9 Oct 2025 | 12 Jun 2026 | |||||
| PT-141 | 4 | 25 Sep 2025 | 19 Jan 2026 | |||||
| Retatrutide | 68 | 4 Aug 2025 | 22 Jun 2026 | |||||
| Semaglutide | 5 | 24 Oct 2025 | 22 Jun 2026 | |||||
| TB-500 | 9 | 4 Aug 2025 | 23 Jun 2026 | |||||
| Tesamorelin | 26 | 11 Aug 2025 | 24 Jun 2026 | |||||
| Tirzepatide | 50 | 31 Aug 2025 | 6 May 2026 | |||||
The Wuhan Wansheng Biotechnology samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Most recent Wuhan Wansheng Biotechnology tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Variant | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 24 Jun 2026 | Tesamorelin | View | 10mg | 10.9mg | +9.0% | 99.90% | TSM-2605-1 | Silver label / Silver crimp / Clear Blue cap | Lab E | Public | ||
| 23 Jun 2026 | TB-500 | View | Thymosin Beta-4 | 20mg | 18.3mg | -8.5% | 99.70% | (no batch ID) | White label / Azul crimp / Clear cap | Lab E | Public | |
| 23 Jun 2026 | BPC-157 | View | 20mg | 19.6mg | -2.0% | 99.30% | (no batch ID) | White label / Silver crimp / Clear Blue cap | Lab E | Public | ||
| 22 Jun 2026 | Retatrutide | View | 50mg | 46.2mg | -7.6% | 99.90% | (no batch ID) | White label / Black crimp / Clear Blue cap | Lab E | Public | ||
| 22 Jun 2026 | Semaglutide | View | 20mg | 20.7mg | +3.5% | 99.90% | (no batch ID) | White label / Copper crimp / Clear cap | Lab E | Public | ||
| 12 Jun 2026 | Melanotan II | View | 10mg | 10.1mg | +1.0% | 99.90% | WWB-ML10-26-04 | (no data) | Lab E | Public | ||
| 12 Jun 2026 | GHK-Cu | View | 100mg | 94.9mg | -5.1% | 99.90% | WWB-CU100-26-04 | (no data) | Lab E | Public | ||
About Wuhan Wansheng Biotechnology Test Results From Finnrick
Wuhan Wansheng Biotechnology is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 12 products and 243 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud). Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Wuhan Wansheng Biotechnology Testing Activity & Score Summary
In the past 30 days, Finnrick has published 9 new test results for Wuhan Wansheng Biotechnology, and 25 in the past three months. The overall dataset includes 243 tested samples with an average score of 6.9/10 across all products.
Across 243 identity-tested samples, 98% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 90% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Tirzepatide (50 tests, 98% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 2.8 to 10.0 (average 7.0/10), suggesting significant batch-to-batch differences.
- Retatrutide (68 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 4.1 to 10.0 (average 7.5/10), suggesting significant batch-to-batch differences.
- Tesamorelin (26 tests, 96% identity pass, median purity 98.9%) — Test scores are highly variable, ranging from 0.0 to 10.0 (average 5.5/10), suggesting significant batch-to-batch differences.